Literature DB >> 29610125

Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.

Samy Suissa1,2.   

Abstract

Entities:  

Keywords:  cohort studies; database; diabetes mellitus, type 2; drug effects; sodium-glucose transport proteins

Mesh：

Substances：

Year:  2018        PMID： 29610125     DOI： 10.1161/CIRCULATIONAHA.117.032799

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  11 in total

Review 1.  Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.

Authors:  Elisabetta Patorno; Sebastian Schneeweiss; Shirley V Wang
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

2.  Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Authors:  Elisabetta Patorno; Ajinkya Pawar; Jessica M Franklin; Mehdi Najafzadeh; Anouk Déruaz-Luyet; Kimberly G Brodovicz; Steven Sambevski; Lily G Bessette; Adrian J Santiago Ortiz; Martin Kulldorff; Sebastian Schneeweiss
Journal:  Circulation       Date:  2019-04-08       Impact factor: 29.690

3.  Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.

Authors:  Meir Schechter; Cheli Melzer-Cohen; Aliza Rozenberg; Ilan Yanuv; Gabriel Chodick; Avraham Karasik; Mikhail Kosiborod; Ofri Mosenzon
Journal:  Cardiovasc Diabetol       Date:  2021-08-18       Impact factor: 9.951

4.  Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.

Authors:  Atsunori Kashiwagi; Shingo Shoji; Satoshi Onozawa; Yoshinori Kosakai; Miina Waratani; Yuichiro Ito
Journal:  J Diabetes Investig       Date:  2022-04-09       Impact factor: 3.681

5.  Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study.

Authors:  Jacob A Udell; Zhong Yuan; Patrick Ryan; Toni Rush; Nicholas M Sicignano; Michael Galitz; Norman Rosenthal
Journal:  Endocrinol Diabetes Metab       Date:  2019-10-15

6.  The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.

Authors:  Elisabetta Patorno; Mehdi Najafzadeh; Ajinkya Pawar; Jessica M Franklin; Anouk Déruaz-Luyet; Kimberly G Brodovicz; Adrian J Santiago Ortiz; Lily G Bessette; Martin Kulldorff; Sebastian Schneeweiss
Journal:  Endocrinol Diabetes Metab       Date:  2019-11-26

7.  Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.

Authors:  Yutaka Seino; Dae Jung Kim; Daisuke Yabe; Elise Chia-Hui Tan; Wook-Jin Chung; Kyoung Hwa Ha; Masaomi Nangaku; Koichi Node; Riho Klement; Atsutaka Yasui; Wei-Yu Lei; Sunwoo Lee; Moe H Kyaw; Anouk Deruaz-Luyet; Kimberly G Brodovicz; Wayne H-H Sheu
Journal:  Endocrinol Diabetes Metab       Date:  2020-09-16

8.  Healthcare resource utilization in patients treated with empagliflozin in East Asia.

Authors:  Wayne H-H Sheu; Yutaka Seino; Elise Chia-Hui Tan; Daisuke Yabe; Kyoung Hwa Ha; Masaomi Nangaku; Wook-Jin Chung; Koichi Node; Atsutaka Yasui; Wei-Yu Lei; Sunwoo Lee; Anastasia Ustyugova; Riho Klement; Anouk Deruaz-Luyet; Moe H Kyaw; Dae Jung Kim
Journal:  J Diabetes Investig       Date:  2022-01-11       Impact factor: 3.681

9.  Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.

Authors:  Kristian B Filion; Lisa M Lix; Oriana Hy Yu; Sophie Dell'Aniello; Antonios Douros; Baiju R Shah; Audray St-Jean; Anat Fisher; Eric Tremblay; Shawn C Bugden; Silvia Alessi-Severini; Paul E Ronksley; Nianping Hu; Colin R Dormuth; Pierre Ernst; Samy Suissa
Journal:  BMJ       Date:  2020-09-23

10.  Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments.

Authors:  Sebastian Schneeweiss; Elisabetta Patorno
Journal:  Endocr Rev       Date:  2021-09-28       Impact factor: 19.871
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.